EADVirtual 2020 29th Congress

Upadacitinib improved symptoms, QoL in moderate-to-severe AD

Roshini Claire Anthony, 20201216180001

Upadacitinib monotherapy improved symptoms and quality of life (QoL) in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to the phase III Measure Up 1 and 2 studies presented at EADV 2020.

Secukinumab improves PASI score for paediatric psoriasis

Elaine Soliven, 20201204100808

Treatment with low-dose (LD) or high-dose (HD) secukinumab significantly improved Psoriasis Area and Severity Index (PASI)* scores in paediatric patients with severe chronic plaque psoriasis, according to a study presented at EADV 2020.

Gel from tree bark: First effective treatment for epidermolysis bullosa

Gel from tree bark EASEs rare skin disease

Pearl Toh, 20201124141000

A topical gel treatment derived from birch bark significantly speeds up wound healing compared with standard care in patients with epidermolysis bullosa (EB) lesions, according to the EASE trial presented at the EADV 2020 Conference — representing the first-ever treatment to show positive results for the rare skin disorder.

Apremilast improves QoL in adults with scalp psoriasis

Elaine Soliven, 20201124000000

Treatment with apremilast led to significantly improved patient-reported quality of life (QoL) outcomes in patients with moderate-to-severe plaque psoriasis of the scalp, according to the STYLE* study presented at EADV 2020.

Nanoparticle technology may take the stink out of smelly feet

Audrey Abella, 20201119100000

Socks coated with zinc oxide nanoparticles (ZnO-NPs), a suitable textile additive, were effective in preventing bromodosis and the development of pitted keratolysis (PK), a Thai study suggests.

Tildrakizumab benefit in chronic plaque psoriasis sustained at 5 years

Roshini Claire Anthony, 20201118180001

The efficacy of tildrakizumab in chronic moderate-to-severe* plaque psoriasis is maintained after 5 years of treatment, final pooled analyses of the phase III reSURFACE 1 and reSURFACE 2 trials showed.

Modified glutathione cream effective in mild-to-moderate rosacea

Stephen Padilla, 20201113120000

The modified glutathione (GSH-C4) with beta glycyrrhetic and azelaic acids cream is effective in the treatment of mild-to-moderate rosacea, with local tolerability consistent with other antirosacea medications, according to a study presented at the 29th Congress of the European Academy of Dermatology and Venereology (EADV 2020).

Acne vulgaris linked to insulin resistance

Stephen Padilla, 20201112130000

Levels of insulin resistance markers tend to be elevated in patients with acne vulgaris, supporting the association between acne vulgaris and insulin resistance, according to the results of a systematic review and meta-analysis.

CTP-543 maintains hair regrowth in adults with hair loss

Audrey Abella, 20201112100000

Adults with moderate-to-severe alopecia areata (AA) had sustained or improved hair regrowth with the oral Janus kinase (JAK) inhibitor CTP-543, results of an open-label extension (OLE) study suggest.

Oral selective JAK1 inhibitor a win in hidradenitis suppurativa

Jairia Dela Cruz, 20201111140000

INCB054707, an oral Janus kinase (JAK)1 inhibitor, shows promise in the treatment of moderate-to-severe hidradenitis suppurativa, reducing the abscess and inflammatory nodule count in addition to having an acceptable safety profile, according to data from two phase II trials.